Flu Epidemic Officially Over in Belgium | Sciensano Data

The influenza epidemic in Belgium has officially ended, according to figures released by the Sciensano health institute. The epidemic lasted approximately three months, prompting a period of ‘code orange’ alert in January and February to help curb the spread of the virus.

Navigating the Winter Wave: What the End of the Epidemic Means

While the term “super flu” circulated in some discussions, the season’s impact, though significant, didn’t reach the levels of a truly exceptional outbreak. The Sciensano data indicates a sustained period of increased influenza activity, but not an unprecedented surge. What we have is a relief for healthcare systems that were already under pressure from other respiratory illnesses, like RSV, as reported earlier this year. The Respi-Radar, Sciensano’s monitoring tool, briefly exceeded the threshold for ‘code red’ – the highest alert level – for specific indicators, signaling substantial strain on resources. However, the overall situation remained at ‘code orange’, indicating significant pressure but not complete overwhelm.

The ‘code orange’ alert, activated by the Risk Management Group (RMG) of the Federal Public Health Service, triggered recommendations for increased preventative measures. These included staying home when sick and wearing masks in crowded places, particularly for those with mild symptoms and when interacting with vulnerable individuals or healthcare personnel. These measures, while not mandates, aimed to reduce transmission and protect those most at risk of severe complications.

Understanding the Numbers: Influenza Activity in Belgium

Throughout the epidemic, consultations with general practitioners for flu-like symptoms rose sharply, peaking at 676 per 100,000 inhabitants during the week of January 19th to 25th – more than double the rate observed at the beginning of January. Wastewater testing also confirmed strong circulation of respiratory viruses. Analysis of samples from doctors’ offices revealed that influenza and RSV were the predominant circulating viruses, while COVID-19 remained at a low level. Hospital admissions for severe acute respiratory infections also increased, reaching 23.9 per 100,000 inhabitants, though these figures lag by a week.

It’s important to remember that influenza impacts different populations differently. While generally a mild illness, it can lead to dangerous complications in older adults, pregnant women, and individuals with underlying health conditions. Sciensano emphasizes that vaccination remains the most effective way to prevent these complications and reduce the risk of hospitalization. On average, approximately 500,000 people in Belgium are affected by influenza each year, representing between 2% and 8% of the population. A moderate epidemic typically affects around 5% (550,000 out of 11 million), while a stronger epidemic can impact as many as 10% (1.1 million). Approximately 1 in 1,000 flu patients requires hospitalization due to complications, and over 90% of influenza-related deaths occur in individuals aged 65 or older. More detailed statistics are available on the Sciensano website.

Beyond Belgium: A European Perspective

The influenza situation in Belgium mirrors trends observed across Europe. The European Centre for Disease Prevention and Control (ECDC) provides comprehensive data on influenza activity throughout the continent. You can uncover the latest European influenza surveillance data on the ECDC website. Globally, the World Health Organization (WHO) estimates that influenza causes 3 to 5 million severe infections and 250,000 to 500,000 deaths annually.

The Role of Surveillance and Future Preparedness

Sciensano plays a crucial role in monitoring influenza activity in Belgium. The institute coordinates a network of sentinel doctors, laboratories, and hospitals to continuously evaluate the intensity and impact of the epidemic. As the National Reference Centre (NRC) for influenza viruses, Sciensano also oversees the quality control of influenza vaccines before they are released to the market, working in collaboration with the European network of Official Medicines Control Laboratories (OMCLs). This rigorous testing ensures the safety and effectiveness of the vaccines.

The end of the epidemic doesn’t signal an end to surveillance. Sciensano will continue to monitor influenza activity, tracking circulating strains and assessing the effectiveness of the current vaccine. This ongoing surveillance is essential for informing future vaccination strategies and preparing for potential future outbreaks. The data collected also helps to refine public health recommendations and ensure that resources are allocated effectively.

What to Expect in the Coming Months

While the current epidemic has subsided, it’s important to remain vigilant. Influenza viruses are constantly evolving, and recent strains can emerge. The timing and severity of future outbreaks can vary. Public health officials will continue to monitor the situation closely and provide updates as needed. Individuals can take steps to protect themselves and others by practicing decent hygiene, such as frequent handwashing, and staying up-to-date on vaccinations. Further information on the recent epidemic and preventative measures can be found on VRT News.

The experience of this past winter underscores the importance of a robust public health infrastructure and ongoing investment in surveillance and research. By learning from past outbreaks, we can better prepare for future challenges and protect the health of the population.